Written by Kate McDonald on .
Interoperability divide in small and large practices, New York HIEs launch SMART on FHIR app, White House talks to Epic and Cerner on COVID antivirals, Emotet botnet makes a return, Singapore’s Hello Health to list on ASX, UK data sharing bill, wearable sensors and COVID vax, Biofourmis reaches unicorn status, Palanitr to build federated data platform for NHS
A fragmented EHR market is fueling interoperability divide, says ONC study
Healthcare IT News ~ Kat Jercich ~ 27/04/2022
Researchers from the Office of the National Coordinator for Health IT found substantial differences between solo practice physicians and large practice physicians when it came to data exchange capabilities.
NY HIEs launch SMART on FHIR app to enhance interoperability
EHR Intelligence ~ Sarai Rodriguez ~ 25/04/2022
The SMART on FHIR application will allow providers to access HIE information directly within their workflows, improving interoperability and data access.
Medtech Hello Health in $20m pre-IPO round
Australian Financial Review ~ Anthony Macdonald ~ 28/04/2022
Singapore-based medically reviewed content business Hello Health is raising $20 million to expand into doctor-patient bookings and digital pharmacies, as it set its sights on an ASX listing next year.
Health and Care Bill given Royal Assent and becomes law
Digital Health News ~ Hannah Crouch ~ 28/04/2022
The Health and Care Bill has become law and includes measures which are targeted at supporting data sharing between health and social care. The bill has been backed by £36 billion over the next three years through the Health and Care Levy.
mHealth wearables can track physiological responses to COVID-19 vaccine
mHealth Intelligence ~ Mark Melchionna ~ 26/04/2022
Scripps researchers found that wearable sensors could help track physiological and immune responses after getting the COVID-19 vaccine, including heart rate, sleep, and activity levels.
Biofourmis reaches unicorn status with $300M Series D
MobiHealthNews ~ Emily Olsen ~ 26/04/2022
Coming nearly two years after the company’s $100 million Series C, Biofourmis tallied its total raise at $445 million.